Suppr超能文献

美国医用大麻许可证持有者的资格条件。

Qualifying Conditions Of Medical Cannabis License Holders In The United States.

机构信息

Kevin F. Boehnke (

Saurav Gangopadhyay is a consultant at Deloitte in Chicago, Illinois.

出版信息

Health Aff (Millwood). 2019 Feb;38(2):295-302. doi: 10.1377/hlthaff.2018.05266.

Abstract

The evidence for cannabis's treatment efficacy across different conditions varies widely, and comprehensive data on the conditions for which people use cannabis are lacking. We analyzed state registry data to provide nationwide estimates characterizing the qualifying conditions for which patients are licensed to use cannabis medically. We also compared the prevalence of medical cannabis qualifying conditions to recent evidence from the National Academies of Sciences, Engineering, and Medicine report on cannabis's efficacy in treating each condition. Twenty states and the District of Columbia had available registry data on patient numbers, and fifteen states had data on patient-reported qualifying conditions. Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (64.9 percent in 2016). Of all patient-reported qualifying conditions, 85.5 percent had either substantial or conclusive evidence of therapeutic efficacy. As medical cannabis use continues to increase, creating a nationwide patient registry would facilitate better understanding of trends in use and of its potential effectiveness.

摘要

大麻在不同病症中的治疗效果的证据差异很大,并且缺乏关于人们使用大麻的病症的综合数据。我们分析了州登记数据,提供了全国性的估计数据,描述了患者获得医用大麻许可的合格病症。我们还将医用大麻合格病症的流行率与最近美国国家科学院、工程院和医学院关于大麻治疗每种病症的功效的报告中的证据进行了比较。20 个州和哥伦比亚特区有关于患者数量的登记数据,15 个州有关于患者报告的合格病症的数据。慢性疼痛是目前和历史上最常见的医用大麻患者报告的合格病症(2016 年为 64.9%)。在所有患者报告的合格病症中,85.5%有充分或确凿的治疗效果证据。随着医用大麻的使用持续增加,建立一个全国性的患者登记系统将有助于更好地了解使用趋势及其潜在的有效性。

相似文献

4
Cannabis for Chronic Pain: Challenges and Considerations.大麻治疗慢性疼痛:挑战与考量。
Pharmacotherapy. 2018 Jun;38(6):651-662. doi: 10.1002/phar.2115. Epub 2018 May 16.
6
Medical Cannabis And Chronic Pain.医用大麻与慢性疼痛
Health Aff (Millwood). 2019 Apr;38(4):694. doi: 10.1377/hlthaff.2019.00170.
8
Policy Ahead of the Science: Medical Cannabis Laws Versus Scientific Evidence.科学之前的政策:医用大麻法律与科学证据
Psychiatr Clin North Am. 2022 Sep;45(3):347-373. doi: 10.1016/j.psc.2022.05.002. Epub 2022 Aug 1.
9
Medical Cannabis for the Primary Care Physician.基层医疗医生的医用大麻
J Prim Care Community Health. 2019 Jan-Dec;10:2150132719884838. doi: 10.1177/2150132719884838.

引用本文的文献

8
The Pharmacology of Cannabinoids in Chronic Pain.大麻素在慢性疼痛中的药理学
Med Cannabis Cannabinoids. 2025 Feb 5;8(1):31-46. doi: 10.1159/000543813. eCollection 2025 Jan-Dec.

本文引用的文献

2
Behind Schedule - Reconciling Federal and State Marijuana Policy.进度滞后——协调联邦与州的大麻政策
N Engl J Med. 2018 Aug 9;379(6):501-504. doi: 10.1056/NEJMp1804408. Epub 2018 Jul 11.
9
Effects of Legal Access to Cannabis on Scheduled II-V Drug Prescriptions.大麻合法准入对 II-V 类管制药物处方的影响。
J Am Med Dir Assoc. 2018 Jan;19(1):59-64.e1. doi: 10.1016/j.jamda.2017.07.017. Epub 2017 Sep 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验